News | January 31, 2022
Cipla has strong traction in India and the US: ICICI Direct
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
It is the generic version of molnupiravir
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
It plans to deliver over 300 million doses to the Indian government
Flattish volume growth and subdued new launches were key factors for last month
2022 is going to be the year of opportunities and innovations from the medical industry in India
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Two out of three people under the age of 40 are at risk of prediabetes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
